Fundraising Fox
Page Therapeutics
6 employees on LinkedIn · 2 known investors
Find your way into Page Therapeutics
Sign up to see every warm intro you have to Page Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Page Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis. Its lead work includes preclinical models and a proof-of-concept clinical trial in breast cancer patients.
Founders & leadership
NA
Nicola AcetoCo-founder, Chief Science OfficerHe holds a full professorship in molecular oncology at ETH Zürich, which he joined in 2021 as associate professor, after leading a research group and serving as assistant professor of oncology at the University of Basel. He completed his doctorate and a postdoctoral fellowship at the Friedrich Miescher Institute for Biomedical Research, followed by a research fellowship at the MGH Cancer Center and Harvard Medical School and an associate membership at the Broad Institute of MIT and Harvard.
CR
Christoph RochlitzCo-founder & Chief Medical OfficerRochlitz is co-founder and Chief Medical Officer of PAGE Therapeutics and Professor Emeritus of Medical Oncology at the University of Basel, where he previously led the Oncology department and Cancer Centre. He completed medical training at universities in Heidelberg, Berlin, Montpellier, and Cambridge, followed by oncology residencies in Germany and Switzerland and postdoctoral research at UCSF and Institut Pasteur; his clinical career focused on breast cancer trials until his 2022 retirement.
PD
Prof. Dr. Med. Christoph RochlitzCo-founder, Chief Medical Officer
DS
Daniele ScarinciChief Executive Officer / Executive DirectorHe co-founded XGEN Venture SGR S.p.A. in 2021 and serves as its managing partner. He chairs the board of Tethis S.p.A., where he previously served as acting CEO and non-executive director, and sits on the board of Gesynta Pharma AB.
KV
Katharina VenturiChief Operating OfficerKatharina Venturi brings 14+ years of drug development experience across oncology, immunology, and cardiovascular indications, working with small molecules, therapeutic antibodies, and engineered compounds in both large pharmaceutical companies and startups. She has led project teams through preclinical and early clinical development stages and has expertise in regulatory processes and clinical trial strategy.
Investors · 2
Claris Ventureslisted by Claris VenturesTorino
How we know: Claris Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Page Therapeutics do?
- PAGE Therapeutics is an oncology drug development company developing compounds that disrupt cell-cell adhesion to dissolve circulating tumor cell (CTC) clusters and block cancer metastasis. Its lead work includes preclinical models and a proof-of-concept clinical trial in breast cancer patients.
- Who founded Page Therapeutics?
- Page Therapeutics was founded by Nicola Aceto, Christoph Rochlitz, Prof. Dr. Med. Christoph Rochlitz.
- Who are Page Therapeutics's investors?
- Page Therapeutics's investors include Claris Ventures, XGEN Venture.